<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24322">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02790125</url>
  </required_header>
  <id_info>
    <org_study_id>IM018-001</org_study_id>
    <nct_id>NCT02790125</nct_id>
  </id_info>
  <brief_title>A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine if single doses of BMS-986166 are safe and
      well tolerated in healthy male subjects and female subjects of non-childbearing potential.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of All Adverse Events (AEs)</measure>
    <time_frame>Baseline Day -1 to Day 65</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline Day -1 to Day 65</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of all All Adverse Events (AEs)</measure>
    <time_frame>Baseline Day -1 to Day 65</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in electrocardiogram(ECG) results</measure>
    <time_frame>Baseline Day -1 to Day 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in body temperature</measure>
    <time_frame>Baseline Day -1 to Day 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in respiratory rate</measure>
    <time_frame>Baseline Day -1 to Day 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in seated blood pressure</measure>
    <time_frame>Baseline Day -1 to Day 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in heart rate</measure>
    <time_frame>Baseline Day -1 to Day 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in clinical laboratory test results</measure>
    <time_frame>Baseline Day -1 to Day 35</time_frame>
    <description>Clinical laboratory testing to include Chemistry analytes and Hematology analytes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in continuous cardiac monitoring data</measure>
    <time_frame>Baseline Day -1 to Day 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in physical examination findings</measure>
    <time_frame>Baseline Day -1 to Day 35</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean difference in nadir heart rate (HR) and its time-matched HR on Day -1</measure>
    <time_frame>Day -1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Largest decrease in HR from time-matched Day -1 baseline</measure>
    <time_frame>Day -1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to nadir HR from time 0 hour (predose)</measure>
    <time_frame>Day -1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in HR at nadir from time-matched Day -1 HR value</measure>
    <time_frame>Day -1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in HR values by timepoint for BMS-986166-treated versus placebo-treated subjects where the baseline is defined as time-matched Day -1 HR value</measure>
    <time_frame>Day -1 to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean difference in absolute lymphocyte count (ALC) values and its time-matched ALC on Day -1 in BMS-986166- treated versus placebo-treated subjects</measure>
    <time_frame>Day -1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Largest decrease in ALC from time-matched Day -1 baseline</measure>
    <time_frame>Day -1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to nadir ALC from time 0 hour (predose)</measure>
    <time_frame>Day -1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in ALC at nadir from time-matched Day -1 value</measure>
    <time_frame>Day -1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in ALC values by timepoint for BMS-986166-treated versus placebo-treated subjects where the baseline is defined as time-matched Day -1 ALC value</measure>
    <time_frame>Day -1 to Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose Panel 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986166 or Placebo matching BMS-986166
Single oral dose of solution as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Panel 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986166 or Placebo matching BMS-986166
Single oral dose of solution as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Panel 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986166 or Placebo matching BMS-986166
Single oral dose of solution as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Panel 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986166 or Placebo matching BMS-986166
Single oral dose of solution as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Panel 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986166 or Placebo matching BMS-986166
Single oral dose of solution as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986166</intervention_name>
    <arm_group_label>Dose Panel 1</arm_group_label>
    <arm_group_label>Dose Panel 2</arm_group_label>
    <arm_group_label>Dose Panel 3</arm_group_label>
    <arm_group_label>Dose Panel 4</arm_group_label>
    <arm_group_label>Dose Panel 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching BMS-986166</intervention_name>
    <arm_group_label>Dose Panel 1</arm_group_label>
    <arm_group_label>Dose Panel 2</arm_group_label>
    <arm_group_label>Dose Panel 3</arm_group_label>
    <arm_group_label>Dose Panel 4</arm_group_label>
    <arm_group_label>Dose Panel 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy female subjects of non-childbearing potential or male subjects as determined
             by medical history, physical examination, vital signs, 12-lead electrocardiogram
             (ECG), and clinical laboratory evaluations

          -  Ages 18 to 55 years

          -  Female subjects must provide documentation of an acceptable method of surgical
             sterilization or meet the protocol criteria for menopause

        Exclusion Criteria:

          -  Any acute or chronic medical illness judged to be clinically significant by the
             Investigator and/or Sponsor medical monitor

          -  Any acute or chronic bacterial, fungal or viral infection, including tuberculosis,
             HIV, hepatitis B or hepatitis C, as defined in the protocol

          -  History of heart disease, neurological disease, eye disorders or gastrointestinal
             disorders or surgery (including cholecystectomy)

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECGs or clinical laboratory tests

          -  Smoking or nicotine use, drug or alcohol abuse within 6 months of starting the study

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ppd Development, Llc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Hunt, Site 0002</last_name>
      <phone>512-447-2985</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>January 24, 2017</lastchanged_date>
  <firstreceived_date>May 31, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
